October 24, 2016 / 6:21 AM / a year ago

GSK seeks U.S. approval for shingles vaccine Shingrix

LONDON, Oct 24 (Reuters) - GlaxoSmithKline said on Monday it had filed its shingles vaccine Shingrix for U.S. regulatory approval, bringing the potential blockbuster a step closer to market.

Shingrix is viewed by analysts as among the British drugmaker’s most promising experimental products, since it has shown greater protection among older recipients than Merck & Co’s rival shot Zostavax.

GSK said it planned to file Shingrix for European and Canadian approval before the end of this year, with Japan following in 2017. (Reporting by Ben Hirschler; Editing by Susan Fenton)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below